TABLE 6.
Comparison of results from studies examining daptomycin PK among patients on hemodialysis
| Regimen and parameter (reference) | Mean (SD) value (crude, unstandardized) |
Mean (SD) value (standardized)a |
||
|---|---|---|---|---|
| Work of Salama et al. | Our data | Work of Salama et al. | Our data | |
| Intradialytic administration of daptomycin (12) | ||||
| Intra-HD AUC | 711.5 (125.9) | 1,164.0 (467.9) | 711.5 (125.9) | 977.7 (386.0) |
| Intra-HD Cmax | 39.7 (7.6) | 45.6 (25.2) | 39.7 (7.6) | 43.6 (23.1) |
| Postdialytic administration of daptomycin (13) | ||||
| AUC0-68 at 6 mg/kg | 1,351 (154) | 1,520 (584.6) | 1,351 (154) | 1,217 (429.5) |
| AUC0-68 at 8 mg/kg | 1,801 (205) | 2,027 (779.4) | 1,801 (205) | 1,622 (572.6) |
a
For intra-HD administration of daptomycin, Monte Carlo simulations were standardized to (i) administration of daptomycin during the last 30 min of HD versus the last 60 min of HD, (ii) 3-h HD session versus 3.5-h HD session, and (iii) 64-kg patient versus actual distribution of weights observed among HD patients under study. For post-HD administration of daptomycin, Monte Carlo simulations were standardized to (i) 4-h HD session versus 3.5-h HD session and (ii) 66-kg patient versus actual distribution of weights observed among HD patients under study.